Albany Medical College Celebrates the Class of 2025
More than 200 degrees were awarded today during Albany Medical College’s 187th Commencement ceremonies at the Saratoga Performing Arts Center.
Medical degrees (MD) were awarded to 124 new physicians. In addition, 42 graduates received Master of Science degrees in Physician Assistant Studies, 12 received either Master of Science or doctoral degrees in the biomedical sciences, and 24 received a doctoral degree in nursing practice from the Center for Nurse Anesthesiology. The Alden March Bioethics Institute awarded five Master of Science degrees and two doctoral degrees.
Speakers included Alan S. Boulos, MD ’94, The Lynne and Mark D. Groban, MD ’67 Distinguished Dean of Albany Medical College; Maggie Gillis, vice chair of the Albany Med Health System board of directors; and student representatives of the Class of 2025.
The keynote speaker was Mitch Warner, best-selling author and managing partner at the Arbinger Institute. With a background in health care culture change, Warner has spoken and consulted for organizations across a range of industries, including the Cleveland Clinic, NASA, and the U.S. Army and Air Force. Warner writes frequently on the effect of individual and organizational mindset on culture and results, as well as leadership, strategy, and performance management.
Warner received an honorary degree. Also receiving an honorary degree was Michael Shy, MD, a 1979 graduate of Albany Medical College. Dr. Shy is a professor of neurology, pediatrics, and molecular physiology and biophysics at the University of Iowa, where he is also director of the Department of Neurology’s Neuromuscular and Neurogenetics divisions, director of the Charcot-Marie-Tooth clinic, and co-director of the Muscular Dystrophy Association clinic.
As a practicing neurologist, Dr. Shy’s clinical expertise lies in neuromuscular disorders, muscular dystrophies, and Charcot-Marie-Tooth (CMT) disease, which encompasses more than 50 types of inherited peripheral neuropathy disorders. He has a special interest in translational research to develop rational therapies for patients with inherited peripheral neuropathies and related neurodegenerative diseases.
